Lindagan, Sayba M.
HRN: 07-62-08 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/28/2025
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
10/28/2025
11/03/2025
IV
2.25gm
Q8
Septicemia Sec To CUTI
Checking Final Appropriateness
Indication: Empiric Type of Infection: Urinary Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes